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Abstract: Lung nodules are frequent findings in chest computed tomography (CT) in patients with
metastatic melanoma. In this study, we assessed the frequency and compared morphologic differences
of metastases and benign nodules. We retrospectively evaluated 85 patients with melanoma (AJCC
stage III or IV). Inclusion criteria were ≤20 lung nodules and follow-up using CT ≥183 days after
baseline. Lung nodules were evaluated for size and morphology. Nodules with significant growth,
nodule regression in line with RECIST assessment or histologic confirmation were judged to be
metastases. A total of 438 lung nodules were evaluated, of which 68% were metastases. At least
one metastasis was found in 78% of patients. A 10 mm diameter cut-off (used for RECIST) showed a
specificity of 95% and a sensitivity of 20% for diagnosing metastases. Central location (n = 122) was
more common in metastatic nodules (p = 0.009). Subsolid morphology (n = 53) was more frequent
(p < 0.001), and calcifications (n = 13) were solely found in non-metastatic lung nodules (p < 0.001).
Our data show that lung nodules are prevalent in about two-thirds of melanoma patients (AJCC
stage III/IV) and the majority are metastases. Even though we found a few morphologic indicators
for metastatic or non-metastatic lung nodules, morphology has limited value to predict the presence
of lung metastases.
Keywords: pulmonary nodules; malignant melanoma; multi-detector computed tomography
1. Introduction
Melanoma is a common skin cancer with an incidence rate of 19.7 per 100,000 and
a death rate of 2.7 per 100,000 [1]. Melanoma has a high potential of metastasizing
lymphatogenously or hematogenously to any organ [2]. In particular, the lungs are fre-
quently affected, as their involvement has been reported in 10–40% of patients [3,4]. Pul-
monary metastatic involvement is associated with short median overall survival (range
6–13 months), thus reflecting the aggressiveness of such advanced oncologic disease [5,6].
Overall survival can be increased by pulmonary metastasectomy, although this proce-
dure can only be performed in selected cases [4]. Routine cross-sectional imaging with
computed tomography (CT), positron emission tomography-CT (PET/CT) or magnetic
resonance tomography for disease staging is not recommended in asymptomatic patients
with American Joint Committee on Cancer (AJCC) stage 0–II due to a high number of false
positive findings [7]. In contrast, imaging (such as chest CT) is recommended for staging
and surveillance of disease in patients with melanoma stage IIb or higher [7,8].
Lung nodules are frequent findings on chest CT scans [9–11]; however, most of
them are benign [12,13]. In the specific setting of staging chest CT in melanoma patients,
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differentiating between metastatic and non-metastatic nodules at baseline CT scans is
difficult although of high clinical and prognostic relevance.
Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or immune RECIST
(iRECIST) to assess tumor response to therapy, a 10 mm long axis diameter cut-off is used
to define target lesions and, therefore, also applicable in lung nodules [8,14]. However,
currently it is unknown how specific this threshold is when applied in lung nodules.
Choosing a non-metastatic lung nodule with a diameter of at least 10 mm for RECIST
assessment at baseline could lead to a wrong classification of treatment response in patient
follow-up.
This study aims (I) to describe the frequency of lung nodules and lung metastases
in a cohort of patients with AJCC stage III or IV, (II) to examine morphologic and size
differences between metastatic and non-metastatic lung nodules and (III) to assess the
sensitivity and specificity for a 10 mm long axis diameter cut-off in pulmonary nodules
used to define target lesions according to the RECIST criteria.
2. Methods
2.1. Overview and Study Design
This retrospective study was approved by the local Ethics Committee and conducted
according to the principles of the Declaration of Helsinki. Patient consent was waived. We
retrospectively evaluated a cohort of 253 advanced stage melanoma patients (AJCC stage III
or IV) undergoing baseline chest CT scans before treatment initiation at the University
Hospital Zurich between 01/2010 and 12/2017. These chest CT scans were screened for
the presence of lung nodules by a radiologist with four years of experience in thoracic
radiology (initials omitted for the review) applying Computer Aided Detection (CAD)
(Syngo.via, Siemens Healthineers, Forchheim, Germany) as a second reader.
2.2. Patients—Baseline Characteristics and Follow-Up
Sex, age, date of baseline and follow-up CT scans, melanoma stage (as defined by
AJCC and TNM Classification of Malignant Tumors), primary tumor site, smoking status
and additional diagnoses at the time of diagnosis were retrospectively recorded. Melanoma
disease progression according to the RECIST classification noted in the electronic medical
record was recorded at the time of the last follow-up CT scan.
2.3. Baseline CT Scan Protocol
Baseline contrast-enhanced chest CT scans were either performed using a second-
generation dual-source 128 slice scanner (SOMATOM Definition Flash, Siemens Health-
ineers, Forchheim, Germany), a second-generation single-source 128 slice scanner (SO-
MATOM Definition Edge, Siemens Healthineers, Forchheim, Germany) or a third-generation
dual-source 192 slice scanner (SOMATOM Force, Siemens Healthineers, Forchheim, Ger-
many) at a tube voltage of 100 kVp or 120 kVp. Tube current time product was adjusted to
patient habitus using automated attenuation-based tube current modulation. The rotation
time was 0.28 s or 0.25 s. The following reconstruction parameters were used: sharp tissue
convolution kernel, slice increment of 1.5 mm and slice thickness of 2.0 mm.
2.4. Lung Nodules
Baseline lung nodules were assessed for size, morphology and location by one radiolo-
gist (C.B., four years of experience in thoracic radiology; Figure 1). Long axis, perpendicular
short axis and average diameter were measured on axial images. Semi-automated seg-
mentation (Syngo.via, Siemens Healthineers, Forchheim, Germany) allowed volumetric
measurements of lung nodules. Sphericity of lung nodules was calculated by the ratio of
short axis diameter to the long axis diameter. Nodules were classified as solid, part-solid or
non-solid as previously described by the Fleischner Society [15]. According to the nodules’
contour, margins were classified as ill-defined (margin irregular and poor), well-defined
(linear demarcation), spiculated (margin radiating) and lobulated (margin undulated).
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Pleural retraction, evidence of air bronchogram, vessel attachment to nodules and nodule
calcification were recorded. Multiple nodules organized as a group within the same lobe
were defined as grouped and single nodules were defined as solitary. Peripheral location
was defined as the outer 1/3 of the lung.
 
Figure 1. Characteristics of lung nodules. (a): solid nodule; (b): part-solid nodule; (c): ill-defined margin; (d): lobulated
margin; (e): spiculated margin; (f): pleural retraction; (g): feeding vessel; (h): air bronchogram.
2.5. Lung Nodules on Follow-Up Chest CT Scan
According to the methodology used by Lee et al. [16], patients were considered as
having pulmonary metastases if any baseline nodules were either pathologically confirmed
as metastases, had increased in size at subsequent follow-up CT or had decreased after
chemotherapy in accordance with RECIST evaluation. If nodules decreased in size while
the RECIST classification of this patient was stable or progressive disease, nodules were
categorized as benign nodules. A diameter change of ≥2 mm in either the long or short
axis was considered as a significant size increase or decrease according to the Fleischner
recommendations [17].
2.6. Statistics
Normality of continuous data was assessed using the Shapiro–Wilk test. Non-normal
distributed continuous data are shown as median and inter-quartile range (IQR). Fisher’s
exact test, Pearson’s chi-squared test and Mann–Whitney U test were used where appropri-
ate. Receiver Operator Characteristic (ROC) and Area Under the Curve (AUC) were used to
predict metastases based on lung nodule sizes. The AUC is shown with a 95% confidence in-
terval (95% CI). ROC curves were compared using DeLong’s test. Statistics were computed
using IBM SPSS, version 25. A two-tailed p < 0.05 was considered as statistically significant.
3. Results
3.1. Patients
Lung nodules were detected on CT scans of 159 patients (63%). Eighty-five patients
(median age, 58 years, 32 females) had follow-up CT conducted ≥183 days after baseline
CT (median follow-up period, 672 days, range 186–3012) and a maximum number of
20 lung nodules per patient and, thus, were included for further assessment in this study
(Figure 2). Seventy-one percent of patients were never-smokers (n = 60). Further baseline
characteristics are shown in Table 1.
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Figure 2. Flow chart illustrating derivation of our final study cohort. American Joint Committee on
Cancer (AJCC). Computed Tomography (CT).
3.2. Evaluation of Lung Nodules
A total of 438 lung nodules were included (Figure 2). The median number of lung
nodules per patient was 4 (interquartile range 2–7). Lung nodules characteristics are
reported in Table 2. Half of the lung nodules were found in the lower lobes (n = 218;
50%) and just over half were detected in the right lung (n = 253; 58%). The median long
axis diameter was 5.5 mm (IQR: 4.2–7.8 mm), median average diameter was 4.7 (IQR:
3.6–6.7 mm) and median volume was 53 mm3 (range 24–144 mm3).
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Table 1. Baseline characteristics of patients.




Age (years) 58 32–80
Smoking status
Never-smokers 60 71%
Current smoker 11 13%
















Head and Neck 15 18%
Body trunk 26 31%
Upper extremities 12 14%
Lower extremities 18 21%
Connective tissue (choroidal) 2 2%
Non-keratinized stratified squamous epithelium (vaginal) 2 2%
Unknown 10 12%
Abbreviation: AJCC, American Joint Committee on Cancer staging system. Categorical data are given as count
(percentage) and continuous data are given as median (range).
3.3. Metastatic Lung Nodules
Sixty-eight percent of lung nodules (n = 296) were metastases. Most lung metastases
resolved during follow-up (n = 210; 71%), 15% decreased in size (n = 44), 14% increased in
size (n = 40) and 1% were resected (n = 2). At least one metastasis was found in the majority
of patients (n = 66, 78%). The median number of metastases per patient was 2 (interquartile
range 1–5). Our results indicate that 94% of patients with ≥3 lung nodules (n = 53) had
at least one metastasis, compared to 50% of patients with ≤2 lung nodules (n = 32). Most
metastases were found in the periphery of the lung (68%).
3.4. Indicators for Metastatic or Non-Metastatic Nodules
Metastatic nodules were slightly larger compared to non-metastatic nodules (median
long axis diameter: 6.0, IQR: 4.4–8.8 mm versus 5.2, IQR: 3.7–6.1 mm; median average
diameter 5.1, IQR: 3.7–7.4 versus 4.2, IQR: 3.3–5.3 and median volume: 71 mm3, IQR:
28–202 mm3 versus 36, IQR: 19–69 mm3; p < 0.001 for both) on baseline CT scans. Further-
more, metastases were slightly rounder with a slightly higher median sphericity index
(0.8, IQR: 0.6–0.8 versus 0.7, IQR: 0.6–0.8; p = 0.038). Figure 3 shows ROC curves for long
axis diameter, average diameter and volume measurements of lung nodules to predict
metastases. Long axis diameter measurements showed an AUC of 0.64 (95% CI: 0.58–0.69).
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Using a long axis diameter cut-off value of 5 mm, specificity and sensitivity to diagnose
metastases were low with 48% and 63%, respectively. Using a cut-off value of 10 mm for
long axis diameter (as proposed in the RECIST criteria), specificity and sensitivity to detect
a metastasis were 95% and 20%, respectively. The AUCs to predict metastases were slightly
higher for average diameter (AUC: 0.64, 95% CI: 0.59–0.70) and volume measurements
(AUC: 0.66, 95% CI: 0.61–0.71), however, without statistical significance (p = 0.325 and
p = 0.059, respectively). Centrally located nodules were more likely to represent metastases
(77% of central nodules versus 64% of peripheral nodules; p = 0.009). Subsolid nodules
were more frequently non-metastatic (p < 0.001). All calcified nodules (n = 13) were non-
metastatic (p < 0.001). Margins of lung nodules, presence of grouped nodules, pleural
retraction, air bronchogram and the feeding vessel sign did not show significant differences
between metastatic and non-metastatic nodules.
Table 2. Characteristics of lung nodules. Morphology of lung nodules and differences between metastatic and non-
metastatic nodules.
All Lung Nodules Non-Metastatic Lesions Metastases p-Value
N = 438 N = 142 32% N = 296 68%
Side
Right 253 58% 82 58% 171 58%
1.00
Left 185 42% 60 42% 125 42%
Lobe
Lower lobe 218 50% 65 46% 153 52%
0.410Upper lobe 177 40% 64 45% 113 38%
Middle lobe 43 10% 13 9% 30 10%
Location
Central 122 28% 28 20% 94 32%
0.009
Periphery 316 72% 114 80% 202 68%
Morphology
Subsolid 53 12% 29 20% 24 8%
<0.001Non-solid 8 2% 7 5% 1 0.3%
Part-solid 45 10% 22 15% 23 8%
Solid 385 88% 113 80% 272 92%
Margin
Ill-defined 24 6% 7 6% 17 6%
0.821
Well-defined 387 88% 129 91% 258 87%
Lobulated 22 5% 5 4% 17 26%
Spiculated 5 1% 1 1% 4 1%
Grouping
Solitary 425 97% 138 97% 287 97%
1.000
Grouped 13 3% 4 3% 9 3%
Pleura retraction
No 431 98% 142 100% 289 98%
0.102
Yes 7 2% 0 0% 7 2%
Air bronchogram
No 436 99.5% 142 100% 294 99%
1.000
Yes 2 0.5% 0 0% 2 1%
Feeding Vessel
No 214 49% 76 54% 138 47%
0.186
Yes 224 51% 66 46% 158 53%
Calcification
No 425 97.0% 129 91% 296 100%
<0.001
Yes 13 3.0% 13 9% 0 0%
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Figure 3. Receiver Operating Characteristic (ROC) curve illustrating the Area Under the Curve
(AUC) for average nodule diameter (blue), maximum long axis diameter (red) and nodule volume
(green) to predict metastases. There were no significant differences between ROC curves calculated
with DeLong’s test (p = 0.059–0.325).
4. Discussion
Even though the presence of lung metastases is likely in advanced stage melanoma
patients [7,18], the high number of non-metastatic lung nodules frequently detected on
CT scans suggests that a relevant proportion of lung nodules detected on CT scans of
melanoma patients are non-metastatic [19]. Our data indicate that (I) 63% of melanoma
patients (AJCC stage III or IV) undergoing staging chest CT showed lung nodules and 78%
of those patients presented with at least one lung metastasis; (II) 68% of all lung nodules
were metastases, with central location and larger size increasing the likelihood for the
presence of metastases. In contrast, subsolid nodules were more frequently non-metastatic
and all calcified nodules were non-metastatic; (III) a cut-off value of 10 mm used to define
a target lesion using the RECIST criteria yielded a high specificity of 95%.
The estimated risk of pulmonary metastases for melanoma patients (AJCC I–IV) is
given as 13% at 5 years, derived from a large prospective comprehensive cancer cen-
ter database of 14,057 melanoma patients [20]. In patients with non-pulmonary cancer,
Hanamiya et al. demonstrated that 75% of patients had lung nodules, and 80% of these
were benign [21]. However, less than 10 patients of the overall cohort of 308 patients had
melanoma, as one study group including patients with melanoma, sarcoma, or testicular
carcinoma comprised 10 patients [21]. In our study (melanoma patients with AJCC stage
III or IV), we found a slightly lower frequency of lung nodules detected on staging CT
(63%), with about 2/3 of nodules representing metastasis (68%).
Previously, it was shown that lung nodule size (>5 mm) and multiplicity of lung
nodules correlate with the presence of metastases [22]. Our results indicate that lung
nodules with increased size are more likely to be metastatic (median volume 71 mm3
compared to 36 mm3; median long axis diameter 6.0 mm compared to 5.2 mm). However,
size differences between metastatic and non-metastatic lung nodules were very small
and size may be an insufficient predictor of metastasis. Accordingly, in our study, a long
axis diameter cut-off value of 5 mm showed a low accuracy to diagnose lung metastasis
(specificity, 48%; sensitivity, 63%). More interestingly, we found a long axis diameter
≥10 mm to have a high specificity of 95% (sensitivity, 20%), indicating that the cut-off
value used to define a target lesion using the RECIST criteria correctly identifies a lung
metastasis in most patients. On the one hand, this result is reassuring as the choice of a
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non-metastatic nodule as a target lesion would hinder correct tumor response assessment
during follow-up. On the other hand, the low sensitivity of this cut-off shows its limited
value for the differentiation of metastatic and non-metastatic lung nodules. Furthermore,
our study showed that the multiplicity of lung nodules can also be used as an indicator for
the presence of lung metastases. Our results indicate that 94% of patients with ≥3 lung
nodules had at least one metastasis, compared to only 50% of patients with ≤2 lung nodules.
In line with previous reports, we found that most metastases are more frequently located
in the periphery of the lung (68%) [23]. However, central lung nodules had a slightly
higher likelihood to be metastases (77% versus 64%). Association of calcification of any
type (diffuse, central, laminated, popcorn patterns) with benign dignity of lung nodules is
widely reported and support our findings that all calcified nodules were non-metastatic
lung nodules [9]. We found subsolid nodules were more likely to be non-metastatic.
Complementing our results, melanoma metastases have been reported to rarely present
with subsolid morphology [23–25]. However, subsolid nodules carry a higher risk for
pulmonary adenocarcinoma [25]. Overall, our study shows that 22% of patients with lung
nodules at chest CT performed for screening of melanoma patients at AJCC stage III or IV
do not have lung metastases. Correct identification of non-metastatic nodules would have
important implications for patient treatment. However, our results show that morphologic
criteria have a limited value for the differentiation of metastatic and non-metastatic lung
nodules. Therefore, biopsy and/or follow-up imaging with chest CT or implementation of
PET/CT [26,27] have to be considered when indeterminate lung nodules are found. Further
research should investigate whether patients with indeterminate lung nodules may benefit
from an increased frequency of follow-up chest CT. Additionally, our results show the
need for further application and research of artificial intelligence-based algorithms [28,29].
Convolutional neuronal networks may have the potential to overcome the limitations of
sheer visual assessment of lung nodule morphology. These neuronal networks are able
to analyze feature maps in which the density of each pixel/voxel of an image is weighted
by convolution matrices and different matrices can be applied for specific tasks, such as
blurring, sharpening or edge detection [30]. These algorithms enable the assessment of
texture metrics, which are not visually perceptible. Previously, Li et al. reported that three
different deep learning architectures reached a lung nodule classification accuracy between
68 and 99.6% and a detection accuracy between 81 and 94% [29].
Our study has some limitations. Firstly, being a single center study, the number of
patients eligible for inclusion in the study, as well as demographic distribution among
patients, was restricted and may be susceptible for referral bias. Secondly, only advanced
clinical stages AJCC III or IV melanoma patients were included. These stages require the
presence of regional lymph node or lymphatic metastases and/or distant non-pulmonary
metastases [7]. With these conditions given, the probability of pulmonary metastases
development is increased [7]. Thirdly, lung nodules with significant size changes over
the follow-up period might not only be of metastatic origin but also from infections or
primary lung cancer, among others. To minimize the erroneous judgement of infectious
nodules as metastases, lung nodules that decreased in size or disappeared during follow-
up were only judged metastases when size decrease was in accordance with the overall
RECIST evaluation [16]. Fourthly, application of our results may be reduced in regions
with endemic infectious diseases resulting in multiple lung nodules such as tuberculosis or
histoplasmosis.
5. Conclusions
Our data show that lung nodules are prevalent in about two-thirds of patients with
advanced stage melanoma (AJCC III or IV) and that the majority (about 70%) of these
are metastases. Even though we found a few morphologic indicators for metastatic or
non-metastatic lung nodules (size, multiplicity of nodules, central location, density and
calcification), morphology has a limited value to predict the presence of lung metastases.
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